CGTX
Cognition Therapeutics, Inc.
$1.21
+4.31%
2026-05-08
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is zervimesine, an orally delivered small molecule to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, which is in Phase 2 clinical studies for the treatment of Alzheimer's disease and Mild Cognitive Impairment, as well as geographic atrophy secondary to dry age-related macular degeneration and dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.
Key Fundamentals
Forward P/E
-3.88
EPS (TTM)
$-0.32
ROE
-88.6%
Profit Margin
0.0%
Debt/Equity
1.86
Price/Book
3.03
Beta
1.81
Market Cap
$104.1M
Avg Volume (10D)
810K
Recent Breakout Signals
No recent breakout signals detected for CGTX.
Recent Price Range (60 Days)
60D High
$1.36
60D Low
$0.55
Avg Volume
1.1M
Latest Close
$1.21
Get breakout alerts for CGTX
Sign up for Breakout Scanner to receive daily notifications when CGTX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Cognition Therapeutics, Inc. (CGTX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CGTX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CGTX operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.